BioNTech

BioNTech’s Oncology Ambition: A Pipeline Poised for Multiple Approvals

kashif hafeez - March 28, 2026

哥本哈根会议成试金石：BioNTech肿瘤管线迎来关键考验

March 28, 2026

BioNTech’s Strategic Pivot Gains Momentum with Key Oncology Data

kashif hafeez - March 26, 2026

BioNTech肿瘤管线集中亮相，肺癌大会成关键催化剂

kashif hafeez - March 25, 2026

BioNTech’s Pivotal Year: Clinical Data Holds Key to Oncology Ambitions

kashif hafeez - March 22, 2026

BioNTech 的精准布局：在肿瘤治疗蓝海中开辟新航道

Brett Shapiro - March 22, 2026

生物科技巨头逆势加仓，BioNTech迎来机构抄底潮

Brett Shapiro - March 19, 2026

从mRNA到抗体疗法：BioNTech战略转型背后的机遇与挑战

angelina - March 18, 2026

Leadership Transition at BioNTech: A Strategic Pivot Underway

angelina - March 18, 2026

BioNTech战略转向：押注抗体疗法的千亿豪赌

kashif hafeez - March 17, 2026

创始人双双离职引发震荡，BioNTech股价遭遇重挫

March 15, 2026

Leadership Transition and Revenue Pressures Weigh on BioNTech Shares

kashif hafeez - March 14, 2026

BioNTech面临双重考验：创始人离任与营收下滑

kashif hafeez - March 14, 2026

创始人卸任与业绩预警双重打击，BioNTech股价遭遇重挫

angelina - March 13, 2026

BioNTech股价遭遇双重打击：创始人离职与营收预警引发市场震荡

Brett Shapiro - March 12, 2026

1...345...9 Page 4 of 9